



## 20 **Abstract**

21 Renal cell carcinoma comprises a variety of entities, the most common being the clear-cell,  
22 papillary and chromophobe subtypes. These subtypes are related to different clinical  
23 evolution; however, most therapies have been developed for clear-cell carcinoma and there is  
24 not a specific treatment based on different subtypes. In this study, one hundred and sixty-four  
25 paraffin samples from primary nephrectomies for localized tumors were analyzed. MiRNAs  
26 were isolated and measured by microRNA arrays. Significance Analysis of Microarrays and  
27 Consensus Cluster algorithm were used to characterize different renal subtypes. The analyses  
28 showed that chromophobe renal tumors are a homogeneous group characterized by an  
29 overexpression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR  
30 629-5p and miR 221-5p. On the other hand, clear cell renal carcinomas presented two  
31 different groups inside this histological subtype, with differences in miRNAs that regulate focal  
32 adhesion, transcription, apoptosis and angiogenesis processes. Specifically, one of the defined  
33 groups had an overexpression of proangiogenic microRNAs miR185, miR126 and miR130a. In  
34 conclusion, differences in miRNA expression profiles between histological renal subtypes were  
35 established. In addition, clear cell renal carcinomas had different expression of proangiogenic  
36 miRNAs. With the emergence of antiangiogenic drugs, these differences could be used as  
37 therapeutic targets in the future or as a selection method for tailoring personalized  
38 treatments.

## 39 **Introduction**

40 Renal carcinoma (RC) is the sixth most common cancer in men and the eight in women, with  
41 73,820 estimated new cases and 14,770 estimated deaths in the United States in 2019 [1].  
42 Two thirds of patients have localized disease and an additional 16% have locoregional disease  
43 (stage III) at diagnosis. A significant proportion of all these patients (up to 40% in stage III) will  
44 eventually relapse [2, 3].

45 Antiangiogenic multi-kinase inhibitors have demonstrated significant efficacy in the metastatic  
46 setting, but have not fulfilled expectations in the adjuvant setting. Sorafenib (SORCE trial),  
47 pazopanib (PROTECT trial) and axitinib (ATLAS trial) failed to improve disease-free survival  
48 when compared with placebo, whereas sunitinib improved disease-free survival but did not  
49 impact in overall survival (STRAC trial) [4-7]. As a consequence, sunitinib has been approved  
50 for adjuvant therapy by the Food and Drug Administration, but not by the European Medicines  
51 Agency and observation remains the standard of care after resection.

52 The current classical classification of renal carcinoma refers to subtypes that have been named  
53 on the basis of predominant cytoplasmic or architectural features, anatomic location,  
54 correlation with a specific disease background, as well as molecular alterations or familial  
55 syndromes [8]. The Cancer Genome Atlas has made considerable efforts to molecularly  
56 characterized different neoplasms, amongst them, renal carcinoma, establishing molecular  
57 characteristics of the different histological renal subtypes [9, 10]. So far, this information has  
58 not contributed to improve the personalized treatment for patients with renal cell carcinoma.

59 Molecular markers different from gene expression could improve our understanding of this  
60 disease. MicroRNAs are small RNA sequences which regulate different cellular processes [11].  
61 They are good molecular biomarkers or even therapeutic targets, especially in clinical paraffin  
62 samples [12]. For these reasons, miRNAs have acquired importance as biomarkers in cancer.

63 The aim of this study is to determine miRNA profiles which allow us to characterize RC  
64 subtypes. Interestingly, we identified two groups of clear cell renal carcinoma (ccRCC) tumors,  
65 one of them with an overexpression of pro-angiogenic microRNAs.

## 66 **Material and methods**

### 67 **Samples**

68 One hundred and sixty-four patients diagnosed with localized RC were recruited for this study.  
69 An observational study was carried out, where all radical and partial nephrectomies performed  
70 at Hospital Universitario 12 de Octubre in Madrid between 1999 and 2008 were included.  
71 Written informed consent was obtained from all patients. The protocol was approved by the  
72 Ethical Committee of Hospital Universitario 12 de Octubre. The evolution of these patients was  
73 obtained from clinical records.

### 74 **miRNA isolation and quantification**

75 396 miRNAs were measured from 164 renal formalin-fixed paraffin-embedded (FFPE) tumor  
76 samples. microRNA extraction and sample processing were done as previously described [13].  
77 Briefly, selected FFPE tumor specimens were cut into serial sections with a thickness of 10  $\mu$ m.  
78 Total RNA was then isolated using the miRNEasy Kit (Quiagen). Purified RNA quality control for  
79 quantity and purity was assessed using an ND-1000 NanoDrop spectrophotometer (Thermo  
80 Fisher Scientific).

### 81 **MicroRNA Arrays**

82 Samples were hybridized to Human miRNA Microarray Release 14.0, 8x15K (Agilent  
83 Technologies). MicroRNA Labeling Kit (Agilent Technologies) was used to label RNA. Basically,  
84 100 ng of total RNA were dephosphorylated and Cyanine 3-pCp molecule was ligated to the 3'  
85 end of each RNA molecule by using T4 RNA ligase. One hundred ng of Cy3 labeled RNA were  
86 hybridized for 20 hours at 55°C in a hybridization oven (G2545A, Agilent) set to 20 rpm in a

87 final concentration of 1X GE Blocking Agent and 1X Hi-RPM Hybridization Buffer, according to  
88 manufacturer's instructions (miRNA Microarray System Protocol, Agilent Technologies). Arrays  
89 were washed according to manufacturer's instructions (miRNA Microarray System Protocol,  
90 Agilent Technologies), dried out using a centrifuge at 1000 rpm for 2 min and scanned at 5µm  
91 resolution on an Agilent DNA Microarray Scanner (G2565BA, Agilent Technologies) equipped  
92 with extended dynamic range (XDR) software. Images provided by the scanner were analyzed  
93 using Agilent's software Feature Extraction version 10.7.3.1. Data were quantile normalized as  
94 previously described [14].

95 Only miRNAs with an average intensity over the 20<sup>th</sup> percentile of the overall intensities and a  
96 detectable signal in at least 10 percent of the hybridized samples considered for further  
97 analysis. Batch effect was corrected using ComBat software [15].

## 98 **Consensus cluster**

99 Consensus cluster using R v3.2.5 and *ConsensusClusterPlus* package was performed to  
100 establish subgroups [16]. Differential miRNAs expression patterns among groups was analyzed  
101 by Significance Analysis of Microarrays (SAM) with MeV 4.9 [17]. SAM performed a t-test  
102 correcting over permutations of the number of samples [18].

103 Targets of these differential miRNAs were searched in miRwalk database [19]. This information  
104 was used to perform a gene ontology analysis and to establish relationship with biological  
105 functions. Gene ontology analyses were done using Enrichr webtool developed by Ma'ayan lab  
106 [20].

## 107 **Statistical analyses**

108 Statistical analyses were done using GraphPad Prism v6. All p-values were two-sided and  
109 considered statistically significant under 0.05.

## 110 Results

### 111 Patient cohort

112 164 renal tumor samples were studied. One hundred of these samples corresponded to clear-  
113 cell carcinomas (ccRCC), 16 to papillary tumors, and 21 chromophobe tumors. Subtype  
114 information was not available for 27 tumors. Of these 164 samples, clinical data were available  
115 for 142 patients. Twenty-three percent of the patients suffered a relapse and the median of  
116 follow-up was 54 months.

	Number of patients	Percentage
<b>Number of patients</b>	142	100%
<b>Furhman grade</b>		
0	1	0.7%
1	7	5%
2	74	52%
3	38	27%
4	7	5%
Unknown	15	10.3%
<b>TNM stage</b>		
T1	97	69%
T2	19	13%
T3	26	18%
<b>Nodal stage</b>		
N0	131	92.3%
N1	5	3.5%
N2	6	4.2%

117 Table 1: Patient characteristics.

### 118 Characterization of differences between histological subtypes

119 A SAM was done to characterize different miRNA expression patterns between histological  
120 groups. It was not possible to find differential miRNAs between papillary and the two other  
121 histological subtypes. SAM showed that chromophobe tumors are a very homogeneous

122 molecular group with a higher expression of miR 1229, miR 10a, miR 182, miR 1208, miR 222,  
123 miR 221, miR 891b, miR 629-5p and miR 221-5p (Fig 1).

124

125 Fig 1: SAM of chromophobe subtype against the rest of tumors. ccRCC= Clear cell renal  
126 carcinoma.

127 On the other hand, ccRCC tumors were split into two different groups in the SAM graph,  
128 suggesting the existence of two molecular groups in ccRCC according the miRNA expression  
129 (Fig 2).

130 Fig 2: SAM of ccRCC tumors against the rest of them. ccRCC= Clear cell renal carcinoma.

### 131 **ccRCC groups' characterization**

132 With the aim of establishing these possible subgroups in ccRCC, a consensus cluster was done.  
133 Consensus cluster grouped patients by the similarity in their expression patterns and it allows  
134 the definition of the optimum number of groups, showing that two different molecular patient  
135 groups existed in ccRCC: ccRCC1 (44 patients) and ccRCC2 (56 patients) (Fig 3).

136 Fig 3: A. Delta graph suggested two groups as the optimum number of groups in these  
137 subtype. B. Tracking plot showed different sample classifications making different number of  
138 groups.

139 Contingency analyses showed that this new ccRCC classification was independent from clinical  
140 data, such as tumor size or nodal status; i.e, there are no differences in tumor size or nodal  
141 status between these two groups ( $p=0.55$  and  $p=0.39$  respectively). However, ccRCC2 tumors  
142 had a lower Furhman grade than ccRCC1 tumors ( $p=0.04$ ).

143 Moreover, a SAM established 136 differentially expressed miRNAs between these two groups  
144 (Fig 4).

145 Fig 4: SAM between two ccRCC identified groups.

146 Experimentally validated targets of these 136 miRNAs were determined using miRwalk  
147 database, and a gene ontology analysis of these genes was performed afterwards. This analysis  
148 showed that these genes were mainly related with focal adhesion, transcription, apoptosis and  
149 angiogenesis processes (Fig 5).

150 Fig 5: Gene ontology of gene targets of the 136 differential miRNAs.

151 Additionally, the two subgroups of ccRCC were associated with a different survival, although  
152 not statistically significant (Fig 6).

153 Fig 6: Survival curves of the two ccRCC groups defined by Consensus Cluster.

154 **New ccRCC groups had differential expression of miRNAs involved in**  
155 **angiogenesis**

156 Interestingly, the two ccRCC subgroups presented differences in expression of some miRNAs  
157 previously associated with angiogenesis. In general, ccRCC2 had more expression of miR185,  
158 miR126 and miR130a, all of them proangiogenic miRNAs (Fig 7).

159 Fig 7: miRNAs related with angiogenesis differentially expressed between two ccRCC groups.

160

## 161 Discussion

162 Renal-cell carcinoma comprises several histological subgroups [8]. The Cancer Genome Atlas  
163 analyzed these histological subtypes and characterized molecular differences between them  
164 [9, 10]. However, all these advances have not been translated into clinical applications yet. For  
165 this reason, further insight into the molecular biology of these tumors is still needed.

166 There are previous classifications of renal histological subtypes based on miRNA signatures,  
167 although a reduce number of miRNAs were used in these analyses [21-23]. In this study, 396  
168 miRNAs were analyzed in 164 RC FFPE samples by microRNA arrays. The main advantage of the  
169 measurement of miRNAs is that they are more stable than longer RNAs or DNA in paraffin  
170 samples [12].

171 SAM showed differences at the miRNA expression level in chromophobe and ccRCC, but no in  
172 papillary tumors. The fact that it was not possible to define differential miRNAs in the papillary  
173 subgroup could be due to the reduced number of this type of tumors in our cohort and the  
174 intrinsic heterogeneity of this group.

175 miR10-a, miR222, and miR221 have been previously described as overexpressed in  
176 chromophobe subtype, what agrees with our results [22, 23].

177 Regarding ccRCC tumors, differential expression pattern analysis suggested the existence of  
178 two different groups inside this histological subtype. This was confirmed by Consensus Cluster,  
179 which defined two groups with different expression in miRNAs whose established targets are  
180 related to angiogenesis, apoptosis, transcription and focal adhesion.

181 Interestingly, three of the miRNAs (miR185, miR126, and miR130a) differentially expressed  
182 between our two ccRCC groups have been previously related with pro-angiogenesis processes.

183 Expression levels of miR185 have been correlated with tumor size, Fuhrman grade, and TNM  
184 staging. The overexpression of this miRNA inhibited proliferation and induced apoptosis [24].  
185 Moreover, elevated miR185 levels were associated with high vascular endothelial growth  
186 factor receptor 2 (VEGFR) expression and therefore a pro-angiogenic activity in ccRCC [25].

187 On the other hand, miR126 inhibits the expression of vascular cell adhesion molecule 1  
188 (VCAM1) implicated in leukocyte adherence to endothelial cells [26]. This miRNA has a pro-  
189 angiogenic function [27]. It is downregulated in metastatic ccRCC versus primary tumors. Its  
190 overexpression is negatively correlated with tumor size and is associated with longer distant  
191 relapse-free survival and overall survival. miR126 overexpression is also related with a  
192 reduction in cellular proliferation [28]. According to these facts, miR126 was underexpressed  
193 in our ccRCC1 group which had a worst prognosis.

194 miR130a were identified as proangiogenic miRNA due to its inhibitory effect in the anti-  
195 angiogenic homeobox GAX and HoxA5 [29]. A relationship between this miRNA and renal  
196 carcinoma had not been previously described.

197 Considering the controversial efficacy of antiangiogenic drugs in the adjuvant setting of renal-  
198 cell carcinoma [30], defining a proangiogenic group may be important to select patients more  
199 likely to benefit from these treatments. In the future, a class predictor could be developed to  
200 define this pro-angiogenic group. Such a predictor should be validated in an independent  
201 cohort.

202 In this work, we have characterized differences between RC histological subtypes using  
203 miRNAs and have defined two ccRCC groups with different expression of pro-angiogenic  
204 miRNAs. Differences between subtypes could be used as therapeutic targets or as a method to  
205 select patients for personalized treatments in the future.

206 **References**

- 207 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7-34.  
208 Epub 2019/01/08. doi: 10.3322/caac.21551. PubMed PMID: 30620402.
- 209 2. Janzen NK, Kim HL, Figlin RA, Beldegrun AS. Surveillance after radical or partial  
210 nephrectomy for localized renal cell carcinoma and management of recurrent disease. *Urol*  
211 *Clin North Am*. 2003;30(4):843-52. PubMed PMID: 14680319.
- 212 3. Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T. Adjuvant therapy in renal cell  
213 carcinoma-past, present, and future. *Semin Oncol*. 2013;40(4):482-91. doi:  
214 10.1053/j.seminoncol.2013.05.004. PubMed PMID: 23972712; PubMed Central PMCID:  
215 PMC3765962.
- 216 4. Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, et al. Adjuvant  
217 sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and  
218 patient-reported outcomes in the S-TRAC trial. *Ann Oncol*. 2018;29(10):2098-104. doi:  
219 10.1093/annonc/mdy329. PubMed PMID: 30412222; PubMed Central PMCID:  
220 PMC6247664.
- 221 5. Lawrence NJ, Martin A, Davis ID, Troon S, Sengupta S, Hovey E, et al. What Survival  
222 Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate-  
223 or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.  
224 *Kidney Cancer*. 2018;2(2):123-31. Epub 2018/08/01. doi: 10.3233/KCA-180038. PubMed PMID:  
225 30740581; PubMed Central PMCID: PMC6364092.
- 226 6. Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al.  
227 Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in  
228 Patients With Localized or Locally Advanced Renal Cell Carcinoma. *J Clin Oncol*.  
229 2017;35(35):3916-23. Epub 2017/09/13. doi: 10.1200/JCO.2017.73.5324. PubMed PMID:  
230 28902533; PubMed Central PMCID: PMC6018511.

- 231 7. Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo  
232 as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS  
233 trial. *Ann Oncol*. 2018;29(12):2371-8. doi: 10.1093/annonc/mdy454. PubMed PMID:  
234 30346481; PubMed Central PMCID: PMC6311952.
- 235 8. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO  
236 Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile,  
237 and Testicular Tumours. *Eur Urol*. 2016;70(1):93-105. Epub 2016/02/28. doi:  
238 10.1016/j.eururo.2016.02.029. PubMed PMID: 26935559.
- 239 9. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The Cancer Genome  
240 Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*.  
241 2018;23(1):313-26.e5. doi: 10.1016/j.celrep.2018.03.075. PubMed PMID: 29617669; PubMed  
242 Central PMCID: PMC6075733.
- 243 10. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al.  
244 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*.  
245 2016;374(2):135-45. Epub 2015/11/04. doi: 10.1056/NEJMoa1505917. PubMed PMID:  
246 26536169; PubMed Central PMCID: PMC6075733.
- 247 11. Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. *J*  
248 *Hematol Oncol*. 2014;7:86. Epub 2014/12/05. doi: 10.1186/s13045-014-0086-0. PubMed  
249 PMID: 25476853; PubMed Central PMCID: PMC4269921.
- 250 12. Kakimoto Y, Tanaka M, Kamiguchi H, Ochiai E, Osawa M. MicroRNA Stability in FFPE  
251 Tissue Samples: Dependence on GC Content. *PLoS One*. 2016;11(9):e0163125. Epub  
252 2016/09/20. doi: 10.1371/journal.pone.0163125. PubMed PMID: 27649415; PubMed Central  
253 PMCID: PMC5029930.
- 254 13. Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, et al.  
255 Combined label-free quantitative proteomics and microRNA expression analysis of breast  
256 cancer unravel molecular differences with clinical implications. *Cancer Res*; 2015. p. 2243-53.

- 257 14. López-Romero P, González MA, Callejas S, Dopazo A, Irizarry RA. Processing of Agilent  
258 microRNA array data. *BMC Res Notes*. 2010;3:18. Epub 2010/01/22. doi: 10.1186/1756-0500-  
259 3-18. PubMed PMID: 20205787; PubMed Central PMCID: PMCPMC2823597.
- 260 15. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data  
261 using empirical Bayes methods. *Biostatistics*. 2007;8(1):118-27. doi:  
262 10.1093/biostatistics/kxj037. PubMed PMID: 16632515.
- 263 16. Monti S, Tamayo P, Mesirov J, Golub T. Consensus Clustering: A Resampling-Based  
264 Method for Class Discovery and Visualization of Gene Expression Microarray Data. *Machine*  
265 *learning*. 2003;52(1):91-118.
- 266 17. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source  
267 system for microarray data management and analysis. *Biotechniques*. 2003;34(2):374-8.  
268 PubMed PMID: 12613259.
- 269 18. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the  
270 ionizing radiation response. *Proc Natl Acad Sci U S A*. 2001;98(9):5116-21. Epub 2001/04/17.  
271 doi: 10.1073/pnas.091062498. PubMed PMID: 11309499; PubMed Central PMCID:  
272 PMCPMC33173.
- 273 19. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk--database: prediction of possible  
274 miRNA binding sites by "walking" the genes of three genomes. *J Biomed Inform*.  
275 2011;44(5):839-47. Epub 2011/05/14. doi: 10.1016/j.jbi.2011.05.002. PubMed PMID:  
276 21605702.
- 277 20. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and  
278 collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics*. 2013;14:128.  
279 Epub 2013/04/15. doi: 10.1186/1471-2105-14-128. PubMed PMID: 23586463; PubMed Central  
280 PMCID: PMCPMC3637064.
- 281 21. Silva-Santos RM, Costa-Pinheiro P, Luis A, Antunes L, Lobo F, Oliveira J, et al. MicroRNA  
282 profile: a promising ancillary tool for accurate renal cell tumour diagnosis. *Br J Cancer*.

283 2013;109(10):2646-53. Epub 2013/10/15. doi: 10.1038/bjc.2013.552. PubMed PMID:  
284 24129247; PubMed Central PMCID: PMC3833202.

285 22. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, et al. Accurate  
286 molecular classification of kidney cancer subtypes using microRNA signature. *Eur Urol*.  
287 2011;59(5):721-30. Epub 2011/01/13. doi: 10.1016/j.eururo.2011.01.004. PubMed PMID:  
288 21272993.

289 23. Powers MP, Alvarez K, Kim HJ, Monzon FA. Molecular classification of adult renal  
290 epithelial neoplasms using microRNA expression and virtual karyotyping. *Diagn Mol Pathol*.  
291 2011;20(2):63-70. doi: 10.1097/PDM.0b013e3181efe2a9. PubMed PMID: 21532496.

292 24. Ma X, Shen D, Li H, Zhang Y, Lv X, Huang Q, et al. MicroRNA-185 inhibits cell  
293 proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-  
294 inactivated clear cell renal cell carcinoma. *Urol Oncol*. 2015;33(4):169.e1-11. Epub 2015/02/17.  
295 doi: 10.1016/j.urolonc.2015.01.003. PubMed PMID: 25700976.

296 25. Yuan HX, Zhang JP, Kong WT, Liu YJ, Lin ZM, Wang WP, et al. Elevated microRNA-185 is  
297 associated with high vascular endothelial growth factor receptor 2 expression levels and high  
298 microvessel density in clear cell renal cell carcinoma. *Tumour Biol*. 2014;35(12):12757-63. Epub  
299 2014/09/14. doi: 10.1007/s13277-014-2602-9. PubMed PMID: 25217984.

300 26. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates  
301 endothelial expression of vascular cell adhesion molecule 1. *Proc Natl Acad Sci U S A*.  
302 2008;105(5):1516-21. Epub 2008/01/28. doi: 10.1073/pnas.0707493105. PubMed PMID:  
303 18227515; PubMed Central PMCID: PMC2234176.

304 27. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates  
305 angiogenic signaling and vascular integrity. *Dev Cell*. 2008;15(2):272-84. doi:  
306 10.1016/j.devcel.2008.07.008. PubMed PMID: 18694566; PubMed Central PMCID:  
307 PMCPMC2604134.

- 308 28. Khella HW, Scorilas A, Mozes R, Mirham L, Lianidou E, Krylov SN, et al. Low expression  
309 of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma. *Am J Pathol.*  
310 2015;185(3):693-703. Epub 2015/01/05. doi: 10.1016/j.ajpath.2014.11.017. PubMed PMID:  
311 25572155.
- 312 29. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that  
313 down-regulates antiangiogenic homeobox genes GAX and HOXA5. *Blood.* 2008;111(3):1217-  
314 26. Epub 2007/10/23. doi: 10.1182/blood-2007-07-104133. PubMed PMID: 17957028;  
315 PubMed Central PMCID: PMC2214763.
- 316 30. Bex A. Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation.  
317 *Ann Oncol.* 2017;28(4):682-4. doi: 10.1093/annonc/mdx014. PubMed PMID: 28104620.


## 318 **Supporting information**

- 319 S1 Table: miRNAs measured in 164 renal carcinoma paraffin samples.
- 320 S2 Table: 136 differential miRNAs between ccRCC groups.






Delta area



B

tracking plot





Apoptosis signaling pathway\_Homo sapiens\_P00006

Angiogenesis\_Homo sapiens\_P00005

CCKR signaling map ST\_Homo sapiens\_P06959

p53 pathway\_Homo sapiens\_P00059

p53 pathway feedback loops 2\_Homo sapiens\_P00059

EGF receptor signaling pathway\_Homo sapiens\_P00059

Ras Pathway\_Homo sapiens\_P00059

FGF signaling pathway\_Homo sapiens\_P00059

PDGF signaling pathway\_Homo sapiens\_P00059

Integrin signaling pathway\_Homo sapiens\_P00059

positive regulation of transcription from RNA polymerase II promoter (GO:0045944)

positive regulation of transcription, DNA-templated (GO:0045893)

negative regulation of transcription from RNA polymerase II promoter (GO:0045945)

negative regulation of transcription, DNA-templated (GO:0045894)

regulation of transcription from RNA polymerase II promoter (GO:0045943)

negative regulation of transcription, DNA-templated (GO:0045894)

regulation of transcription (GO:0006351)

regulation of transcription, DNA-templated (GO:0045893)

nuclear-transcribed (GO:0045893)

protein deubiquitination (GO:0045893)

membrane (GO:0045893)

focal adhesion (GO:0005925)

Golgi apparatus (GO:0005794)

nucleolus (GO:0005730)

centrosome (GO:0005813)

endoplasmic reticulum (GO:0005783)


nuclear membrane (GO:0005638)

mitochondrion (GO:0005739)

nuclear speck (GO:0005638)

intracellular (GO:0005638)

nuclear chromosome (GO:0005638)



P value	0.1659
Hazard Ratio (logrank)	A/B
Ratio (and its reciprocal)	1.687
95% CI of ratio	0.8042 to 3.945

